

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/584,998
				Filing Date	January 16, 2007
				First Named Inventor	LEVY, Andrew
				Art Unit	1634
				Examiner Name	
Sheet	1	of	7	Attorney Docket Number	P-7339-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)				
	A	WO	9001069	1990	SEGEV, et al		<input type="checkbox"/>
	B	WO	98/37419	1998	DELANGHE		<input type="checkbox"/>
	C	WO	2004/060135 A2	22 JULY 2004			<input type="checkbox"/>
	D	WO	01/80712 A2	01 NOVEMBER 2001			<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>
							<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/584,998
				Filing Date	January 16, 2007
				First Named Inventor	LEVY, Andrew
				Art Unit	1634
(use as many sheets as necessary)				Examiner Name	
Sheet	2	of	7	Attorney Docket Number	P-7339-US1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	E	BUHLIN K et al. "Risk factors for cardiovascular disease in patients with periodontitis." Eur Heart J. 2003 Dec;24(23):2099-107.	<input type="checkbox"/>
	F	DE BACQUER D et al. "Haptoglobin polymorphism as a risk factor for coronary heart disease mortality." Atherosclerosis. 2001 Jul;157(1):161-6.	<input type="checkbox"/>
	G	HONG SH et al. "Haptoglobin polymorphism in Korean patients with cardiovascular diseases." Hum Hered. 1997 Sep-Oct;47(5):283-7.	<input type="checkbox"/>
	H	YUSUF S et al. "Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators." N Engl J Med. 2000 Jan 20;342(3):154-60.	<input type="checkbox"/>
	I	LIND P et al. "Risk of myocardial infarction in relation to plasma levels of homocysteine and inflammation-sensitive proteins: a long-term nested case-control study." Angiology. 2003 Jul-Aug;54(4):401-10.	<input type="checkbox"/>
	J	NISHIKAWA T et al. "Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage." Nature. 2000 Apr 13;404(6779):787-90.	<input type="checkbox"/>
	K	OHGAMI N et al. "CD36, serves as a receptor for advanced glycation endproducts (AGE)." J Diabetes Complications. 2002 Jan-Feb;16(1):56-9.	<input type="checkbox"/>
	L	STAMLER J et al. "Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial." Diabetes Care. 1993 Feb;16(2):434-44.	<input type="checkbox"/>
	M	STEINBERG D, (1997) "Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem; 272-20963-6	<input type="checkbox"/>
	N	WILLIAMS, et al, (1992) "Dietary vitamin E and the attenuation of early lesion development in modified Watanabe rabbits." Atherosclerosis 1992 June; 94:153-159.	<input type="checkbox"/>
	O	BROWN BG et al. "Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease." N Engl J Med. 2001 Nov 29;345(22):1583-92.	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JG/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/584,998
				Filing Date	January 16, 2007
				First Named Inventor	LEVY, Andrew
				Art Unit	1634
(use as many sheets as necessary)				Examiner Name	
Sheet	3	of	7	Attorney Docket Number	P-7339-US1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	P	GISSI, Lancet 1999; 354:4477-55	<input type="checkbox"/>
	Q	HODIS HN et al. "Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin Atherosclerosis Prevention Study (VEAPS)." Circulation. 2002 Sep 17;106(12):1453-9.	<input type="checkbox"/>
	R	JIANG XC et al. "Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E." J Biol Chem. 2002 Aug 30;277(35):31850-6. Epub 2002 Jun 24.	<input type="checkbox"/>
	S	LEVY AP et al. "Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study." J Am Coll Cardiol. 2002 Dec 4;40(11):1984-90.	<input type="checkbox"/>
	T	MARCHIOLI R et al. "Antioxidant vitamins and prevention of cardiovascular disease: epidemiological and clinical trial data." Lipids. 2001;36 Suppl:S53-63.	<input type="checkbox"/>
	U	FRANK MB et al. "The Kozak sequence polymorphism of platelet glycoprotein Ibalpha and risk of nonfatal myocardial infarction and nonfatal stroke in young women." Blood. 2001 Feb 15;97(4):875-9.	<input type="checkbox"/>
	V	STEINBERG D et al. "Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis?" Circulation. 2002 Apr 30;105(17):2107-11.	<input type="checkbox"/>
	W	UK Prospective Study Group Diab Care 1998; 21: 1271-1277	<input type="checkbox"/>
	X	WATERS DD et al. "Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial." JAMA. 2002 Nov 20;288(19):2432-40.	<input type="checkbox"/>
	Y	WITZTUM JL et al. "The oxidative modification hypothesis of atherosclerosis: does it hold for humans?" Trends Cardiovasc Med. 2001 Apr-May;11(3-4):93-102.	<input type="checkbox"/>
	Z	BARANY F et al. "The ligase chain reaction in a PCR world." PCR Methods Appl. 1991 Aug;1(1):5-16.	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JG/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/584,998
				Filing Date	January 16, 2007
				First Named Inventor	LEVY, Andrew
				Art Unit	1634
<i>(use as many sheets as necessary)</i>				Examiner Name	
Sheet	4	of	7	Attorney Docket Number	P-7339-US1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	BARANY F. "Genetic disease detection and DNA amplification using cloned thermostable ligase." Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):189-93.	<input type="checkbox"/>
	AB	BROWN BG et al. "Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease." N Engl J Med. 2001 Nov 29;345(22):1583-92.	<input type="checkbox"/>
	AC	FAHY E et al. "Self-sustained sequence replication (3SR): an isothermal transcription-based amplification system alternative to PCR." PCR Methods Appl. 1991 Aug;1(1):25-33.	<input type="checkbox"/>
	AD	GUATELLI JC et al. "Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication." Proc Natl Acad Sci U S A. 1990 Mar;87(5):1874-8.	<input type="checkbox"/>
	AE	MULLIS KB. "The polymerase chain reaction in an anemic mode: how to avoid cold oligodeoxyribonuclear fusion." PCR Methods Appl. 1991 Aug;1(1):1-4	<input type="checkbox"/>
	AF	GOGS JA et al. "Detection of single base mismatches of thymine and cytosine residues by potassium permanganate and hydroxylamine in the presence of tetralkylammonium salts." Nucleic Acids Res. 1990 Dec 11;18(23):6807-14.	<input type="checkbox"/>
	AG	Wu DY et al. "The ligation amplification reaction (LAR)--amplification of specific DNA sequences using sequential rounds of template-dependent ligation." Genomics. 1989 May;4(4):560-9.	<input type="checkbox"/>
	AH	Barlow and Lehrach, Trends Genet., 3:167 (1987)	<input type="checkbox"/>
	AI	CONNER BJ et al. "Detection of sickle cell beta S-globin allele by hybridization with synthetic oligonucleotides." Proc Natl Acad Sci U S A. 1983 Jan;80(1):278-82.	<input type="checkbox"/>
	AJ	FARR CJ et al. "Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes." Proc Natl Acad Sci U S A. 1988 Mar;85(5):1629-33.	<input type="checkbox"/>
	AK	LEVY AP et al. "The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes." Diabetes Care. 2004 Nov;27(11):2767.	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JG/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/584,998
				Filing Date	January 16, 2007
				First Named Inventor	LEVY, Andrew
				Art Unit	1634
(use as many sheets as necessary)				Examiner Name	
Sheet	5	of	7	Attorney Docket Number	P-7339-US1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AL	KWOK S et al. "Effects of primer-template mismatches on the polymerase chain reaction: human immunodeficiency virus type 1 model studies." Nucleic Acids Res. 1990 Feb 25;18(4):999-1005.	<input type="checkbox"/>
	AM	LYONS J et al. "Two G protein oncogenes in human endocrine tumors." Science. 1990 Aug 10;249(4969):655-9.	<input type="checkbox"/>
	AN	PERLMAN PS et al. "Mobile introns and intron-encoded proteins." Science. 1989 Dec 1;246(4934):1106-9.	<input type="checkbox"/>
	AO	URDEA MS et al. "A novel method for the rapid detection of specific nucleotide sequences in crude biological samples without blotting or radioactivity; application to the analysis of hepatitis B virus in human serum." Gene. 1987;61(3):253-64.	<input type="checkbox"/>
	AP	VOGELSTEIN B et al. "Genetic alterations during colorectal-tumor development." N Engl J Med. 1988 Sep 1;319(9):525-32.	<input type="checkbox"/>
	AQ	ABRAMS ES et al. "Comprehensive detection of single base changes in human genomic DNA using denaturing gradient gel electrophoresis and a GC clamp." Genomics. 1990 Aug;7(4):463-75.	<input type="checkbox"/>
	AR	BØRRESEN AL et al. "Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations." Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8405-9.	<input type="checkbox"/>
	AS	HAYASHI K. "PCR-SSCP: a simple and sensitive method for detection of mutations in the genomic DNA." PCR Methods Appl. 1991 Aug;1(1):34-8.	<input type="checkbox"/>
	AT	LERMAN LS et al. "Computational simulation of DNA melting and its application to denaturing gradient gel electrophoresis." Methods Enzymol. 1987;155:482-501.	<input type="checkbox"/>
	AU	LIU Q et al. "Parameters affecting the sensitivities of dideoxy fingerprinting and SSCP." PCR Methods Appl. 1994 Oct;4(2):97-108.	<input type="checkbox"/>
	AV	ORITA M et al. "Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction." Genomics. 1989 Nov;5(4):874-9.	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JG/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	10/584,998
				Filing Date	January 16, 2007
				First Named Inventor	LEVY, Andrew
				Art Unit	1634
(use as many sheets as necessary)				Examiner Name	
Sheet	6	of	7	Attorney Docket Number	P-7339-US1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AW	SCHOLZ RB et al. "Rapid screening for Tp53 mutations by temperature gradient gel electrophoresis: a comparison with SSCP analysis." Hum Mol Genet. 1993 Dec;2(12):2155-8.	<input type="checkbox"/>
	AX	SHEFFIELD VC et al. "Attachment of a 40-base-pair G + C-rich sequence (GC-clamp) to genomic DNA fragments by the polymerase chain reaction results in improved detection of single-base changes." Proc Natl Acad Sci U S A. 1989 Jan;86(1):232-6.	<input type="checkbox"/>
	AY	SMITH FI et al. "Novel method of detecting single base substitutions in RNA molecules by differential melting behavior in solution." Genomics. 1988 Oct;3(3):217-23.	<input type="checkbox"/>
	AZ	WARTELL RM et al. "Detecting base pair substitutions in DNA fragments by temperature-gradient gel electrophoresis." Nucleic Acids Res. 1990 May 11;18(9):2699-705.	<input type="checkbox"/>
	BA	CAMPO, et al, Cardiovasc Drug Rev 1997; 15: 157-173	<input type="checkbox"/>
	BB	KITA T et al. "Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia." Proc Natl Acad Sci U S A. 1987 Aug;84(16):5928-31.	<input type="checkbox"/>
	BC	MAK IT et al. "Protective effects of dihydropyridine Ca-blockers against endothelial cell oxidative injury due to combined nitric oxide and superoxide." Pharmacol Res. 2002 Jan;45(1):27-33.	<input type="checkbox"/>
	BD	Meng CQ et al. "Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis." Bioorg Med Chem Lett. 2002 Sep 16;12(18):2545-8.	<input type="checkbox"/>
	BE	SAGACH, et al, Pharma Res 202; 45: 435-439	<input type="checkbox"/>
	BF	YOSHIDA N et al. "Inhibitory effect of a novel water-soluble vitamin E derivative on atherosclerosis in rabbits." Atherosclerosis. 2002 May;162(1):111-7.	<input type="checkbox"/>
	BG	BLUM S et al. "Haptoglobin genotype determines myocardial infarct size in diabetic mice." J Am Coll Cardiol. 2007 Jan 2;49(1):82-7. Epub 2006 Dec 13.	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JG/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/584,998		
		Filing Date	January 16, 2007		
		First Named Inventor	LEVY, Andrew		
		Art Unit	1634		
		Examiner Name			
Sheet	7	of	7	Attorney Docket Number	P-7339-US1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BH		The Heart Outcomes Prevention Evaluation Study Investigators N Eng J Med 2000; 342: 154-160	<input type="checkbox"/>
BI		Milman ET AL.; Vitamin E Supplementation Reduces Cardiovascular Events In A Subgroup Of Middle-Aged Individual With Both Type 2 Diabetes Mellitus And The Haptoglobin 2-2 Genotype; Journal Of The American Heart Association November 21, 2007	<input type="checkbox"/>
BJ		SUPPLEMENTARY EUROPEAN SEARCH REPORT ISSUED IN EP 04 79 9315; JUNE 26, 2009	<input type="checkbox"/>
BK		OFFICE ACTION ISSUED IN CN 2003801180094/8; JUNE 5, 2009	
BL		DELANGHE J et al. "Haptoglobin polymorphism and peripheral arterial occlusive disease." Atherosclerosis. 1999 Aug;145(2):287-92.	<input type="checkbox"/>
BM		ASLEH R et al. "Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease." Circ Res. 2003 Jun 3;92(11):1193-200. Epub 2003 May 15	<input type="checkbox"/>
BN		LEVY AP et al. "The effect of vitamin therapy on the progression of coronary artery atherosclerosis varies by haptoglobin type in postmenopausal women." Diabetes Care. 2004 Apr;27(4):925-30.	<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file and by the USPTO (to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JC/